myoglobin (mb) is the different cardiac biomarker in heart disease, used to assess reperfusion after thrombolysis.
myoglobin (mb) is the different cardiac biomarker in heart disease, used to assess reperfusion after thrombolysis.
what are the different cardiac biomarkers in heart disease, used to assess reperfusion after thrombolysis?
myoglobin (mb)
Na
Na
in patients with symptoms typical of myocardial ischemia an electrocardiogram must be immediately obtained - e.g., within 10 minutes from first contact with medical or paramedical personnel, including prehospital setting; the electrocardiographic findings will guide the subsequent management. patients with elevation of the st segment (or presumed new left bundle branch block) are treated based on guidelines for st elevation myocardial infarction (stemi) and must undergo reperfusion therapy as soon as possible. serum cardiac biomarkers are routinely obtained and their elevation is necessary for confirming diagnosis of myocardial infarction; however, reperfusion must not be delayed by waiting for the results. patients without the above findings are initially classified as suffering from non st elevation acute coronary syndrome, and subsequent cardiac biomarker results will differentiate between true non st elevation myocardial infarction (nstemi) and unstable angina.
management of acute coronary syndrome